Fast disintegrating crystalline solid dispersions of  simvastatin for incorporation into orodispersible tablets by Pabari, Ritesh M et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
School of Pharmacy Articles School of Pharmacy
1-4-2014
Fast disintegrating crystalline solid dispersions of
simvastatin for incorporation into orodispersible
tablets
Ritesh M. Pabari
Royal College of Surgeons in Ireland, riteshpabari@rcsi.ie
Asha Jamil
Royal College of Surgeons in Ireland, asha1j@hotmail.com
John G. Kelly
Royal College of Surgeons in Ireland
Zebunnissa Ramtoola
Royal College of Surgeons in Ireland, zramtoola@rcsi.ie
This Article is brought to you for free and open access by the School of
Pharmacy at e-publications@RCSI. It has been accepted for inclusion in
School of Pharmacy Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Pabari RM, Jamil A, Kelly JG, Ramtoola Z. Fast disintegrating crystalline solid dispersions of simvastatin for incorporation into
orodispersible tablets. International Journal of Pharmaceutical Investigation. 2014;4(2):51-59.
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/spharmart/11
International Journal of
International Journal of  Pharmaceutical Investigation is indexed with Chemical 
Abstracts, CNKI (China National Knowledge Infrastructure), EBSCO Publishing’s 
Electronic Databases, Global Health, Health & Wellness Research Center, Health 
Reference Center Academic, Hinari, Index Copernicus, MANTIS, National Science 
Library, OpenJGate, PubMed, Pubmed Central, SCOLOAR, SIIC databases, Ulrich’s 
International Periodical Directory 
www.inpharm.org
www.journalonweb.com/jphi
ISSN : 2230-973X
w
w
w.
jp
io
nl
in
e.
or
g
w
w
w.
jp
io
nl
in
e.
or
g
An O  cial Publication of InPharm Association
Pharmaceutical
Investigation
Figure showing the images of  compression coated formulation
Pathuri Lakshmi Sirisha, Govada Kishore Babu, Puttagunta Srinivasa Babu. Int J Pharma Investig 2014;4:77-87.
 International Journal of Pharmaceutical Investigation          •        Volume 4        •        Issue 2        •        April-June  2014        •        Pages 51-106
Vol 4 | Issue 2 | April-June 2014
International Journal of Pharmaceutical Investigation | April 2014 | Vol 4 | Issue 2 51
INTRODUCTION
Simvastatin (SIM), a cholesterol lowering drug, is a lipophilic 
drug with a log P value of 4 with aqueous solubility of ~30 
μg/ml.[1,2] It is categorized as a class II drug according to the 
biopharmaceutics classification system because it has a low 
solubility and high permeability. As for compounds with low 
aqueous solubility, SIM exhibits low and variable bioavailability 
associated with dissolution rate-limited absorption after oral 
administration.[1,3,4]
SIM is one of many pharmaceutical actives which have 
solubility limitation. It is estimated that ~40-50% of drugs 
current or in development have poor solubility and numerous 
formulation strategies have been developed and used over 
the years. A commonly used approach is to formulate solid 
dispersions (SDPs)of the poorly soluble drug using a carrier 
such as polyvinylpyrrolidone in which the drug is molecularly 
dispersed.[5,6] Other strategies include particle size reduction,[7] 
although size reduction methods can cause solid state 
modifications, complexation with cyclodextrins,[8] formation of 
amorphous forms by spray drying.[9,10]
Attempts to increase the solubility of SIM by formulating amorphous 
SDPs of SIM with hydrophilic polymers such as PVP or HPMC 
by spray drying, using organic solvents resulted in an increase in 
solubility and dissolution rate of SIM.[9,11] A major disadvantage of 
amorphous materials however is their instability and reconversion 
to crystallinity and to prevent conversion to the crystalline form, 
demands strict storage conditions of temperature and humidity.
Orodispersible tablets (ODTs) have gained popularity amongst 
the wide population, including the pediatrics, geriatrics and 
patients suffering from dysphagia and emesis.[12] According to the 
Food and Drug Administration  [13] ODTs should have an in vitro 
DT of 30 s or less. Poorly soluble drugs may however increase the 
disintegrating time of ODT as due to their hydrophobicity, they 
can reduce the wetting and water uptake ability of ODTs.[14,15] 
This can be overcome by adding wetting agents and/or surfactants 
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Abstract
Aim: Spray dried solid dispersion (SDP) of crystalline simvastatin (SIM) in a fast disintegrating matrix of superdisintegrants was 
studied as a method to enhance SIM dispersibility, rheology, compactibility and compressibility for incorporation into orodispersible 
tablets (ODTs). Materials and Methods: The superdisintegrants investigated were crospovidone (CP), sodium starch glycollate 
(SSG) and calcium silicate (CS) were spray dried with simvastatin to form SDPs. Results: The SDPs were characterized and the 
median particle size of SDPs was similar or greater than the SIM, contributing to good rheology of SDPs, while the low bulk 
density of SDPs indicated a high compactibility. Interestingly electron micrographs for SDPs showed a CP or CS carrier coating 
of the SIM crystals, contributing to its rheology. Thermal analysis and X-ray diffraction confi rmed that SIM was crystalline in 
the SDPs and no interaction between SIM and any of the carrier(s) was shown by Fourier transform-infra red. Drug content 
analysis showed a SIM content of 90-95% in SDPs containing CP or CS, while a higher SIM content of 143% was found in 
SDP containing SSG. When formulated as ODTs, blend containing SIM SDPs in CP showed ease of tableting, regardless of the 
turret speed. In comparison, tablet blend consisting of a physical mix (PM) of SIM and CP could only be tableted at the lower 
turret speed of 7 rpm. ODTs formulated using SIM SDPs in CP showed a higher extent of dissolution, compared to the ODTs 
containing corresponding PM or the commercially available SIM Zocor® tablets (ANOVA, P < 0.05). Conclusion: SDP using 
disintegrants as carriers may offer an alternative formulation approach for ODTs of poorly soluble drugs.
Key words: Crystallinity, orodispersible tablets, simvastatin, solid dispersion, spray drying, superdisintegrants
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to the blend to encourage wetting. However, addition of 
surfactant/wetting agent may result in processing difficulties 
such as sticking during tableting as most of the surfactants are 
in liquid or wax form or have low melting point.
A possible way of enhancing the disintegration time (DT) of 
ODTs containing poorly soluble drugs by formulating the poorly 
soluble crystalline drugs in a hydrophilic disintegrating matrix as 
a spray dried (SD) SDP for subsequent tableting as ODTs. Such 
a rapid disintegrating SDP of the drug will provide an intimate 
mix of the drug and disintegrant which will enhance wetting, 
disintegration and dissolution of the drug. In addition as SD 
product is often associated with enhanced rheology, this should 
allow for a direct compression material for ease and consistency 
of further processing into ODTs.[16] Superdisintegrants such 
as crospovidone (CP) (Kollidon® CL), croscarmellose sodium 
(Ac-Di-Sol) and sodium starch glycollate (SSG) (Explotab® 
or Primogel®) have been shown to enhance dissolution of 
itraconazole (log P = 5.66) and nifedipine (log P = 2.5) 
attributed to amorphous formation of the drug during formation 
of SDPs by wet massing or solvent deposition.[17,18] Amorphous 
drugs however are associated with reversion to original crystal, 
crystal growth or phase separation which is accompanied by a 
decrease in solubility and dissolution.[19]
During the formation of SDPs, active pharmaceutical ingredients 
(APIs) can also undergo phase transformations into other 
metastable polymorphic form with different physicochemical 
properties. SIM is reported to occur in three different crystalline 
forms; conventionally available and most stable form I, 
orthorhombic which is stable from −1.15°C to the fusion 
temperature (138.85-142.85°C), form II, orthorhombic stable in the 
range −41.15°C- −1.15°C and form III, assigned as monoclinic 
and stable below −41.15°C.[20] At room temperature (RT) however 
there polymorphs should not be present and are not expected to 
form from spray drying at high temperature of ≥90°C.
The aim of this study was to maintain the drug in its crystalline 
form for retention of its stability during product shelf life, while 
providing a disintegrating matrix to facilitate its dissolution and 
hence absorption. We formulated crystalline SIM as a SD SDP 
using the hydrophilic superdisintegrant carriers; CP (Kollidon® 
CL-SF), SSG (Explotab®) and calcium silicate (CS) and 
were subsequently mixed with the direct compression sugar, 
mannitol and tableted as ODTs. An aqueous dispersion was 
used to minimize drug solubilization and hence conversion 
of the drug to amorphous form and forming a crystalline SDP 
[Figure 1]. The superdisintegrants selected were previously 
shown by us to promote wetting and water uptake into ODTs.[15]
MATERIALS AND METHODS
Materials
SIM was bought from Leo Chemical, Mongkok, Kowloon, Hong 
Kong, China, Mannitol 200 (Parteck®) was a gift from Merck 
KGaA, Norman Lauder, Dublin, CP (Kollidon® CL-SF) was a 
gift from BASF, Cheshire, UK, SSG (Explotab®) was a gift from 
JRS Pharma, Germany, CS (RxCIPIENTS™ FM1000) was a gift 
from Huber Engineered, Finland, magnesium stearate was a gift 
from JMB, UK. Zocor® tablets were bought from United Drug 
(Dublin, Ireland).
Preparation of SD SDPs
SDPs were prepared by a conventional spray drying technique 
using a Buchi Mini Spray Dryer B290 (Switzerland) operated 
in an open loop. SIM alone or in combination with the carriers, 
CP or SSG or CS was formulated as an aqueous dispersion (feed 
dispersion) containing 7.5% w/v of total solids at drug to carrier 
weight ratios 1:1. The feed dispersions (100 ml) at a feed flow rate 
of 4.0 ml/min were sprayed in the spray drying chamber using 
compressed air flowing at 414 Nl/h. The inlet drying temperature 
of 90°C was used with air aspirator setting of 40 m3/h. The spray 
drying outlet temperature was monitored and was found to be in 
the range 29-44°C.
The resultant SDPs were recovered, weighed and the percentage 
product yield was calculated using the below equation 1.
Particle size analysis
The particle size of SIM API, carriers, aqueous dispersions of 
SIM API and SIM in combination with various carriers and 
SDPs was measured in triplicates by laser diffraction analysis 
using a Mastersizer 2000 (Malvern Instruments, U.K.). For 
measurements in the dry state, dry dispersion attachment 
(Scirocco™) was used, whereas when in aqueous dispersion, 
the wet dispersion cell of the Mastersizer 2000 (Hydro 2000SM; 
Malvern Instruments, Malvern, Worcestershire, UK) was used.[21] 
The particle size median diameter (D50%) and size distribution 
(Span) are reported.
Morphology
The surface morphology of SIM, carriers and SIM SDPs were 
examined using a Variable Pressure Field Emission Scanning 
Electron Microscope (Hitachi S-4300 USA). Samples were prepared 
as previously described by Ramtoola et al.,[21] the gold coated 
specimen was then photographed at an appropriate magnification 
of ×200 to 25 kx.
Figure 1: Schematic representation of the structure of rapidly 
disintegrating solid dispersion
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Rheology
Carrs compressibility index (CI) value was used as an indicator 
of the rheological property of SIM API and SIM SDPs. CI 
was derived from the bulk and tapped density values using 
equation 2. The bulk and the tapped density (1000 taps) of each 
sample was determined in triplicates as described in the British 
Pharmacopoeia (BP)[22] using a tapped density volumeter (Copley 
Instruments, Nottingham, UK). The CI was interpreted by the 
generally accepted scale of flowability outlined in the BP 2008.
Where ρtapped and ρbulk are tapped and bulk densities, respectively.
Solid state analysis
Differential scanning calorimetry (DSC)
DSC was conducted using a DSC Q100 V9.0 Build 275 (TA 
Instruments, New Castle, Delaware, USA). The analysis was 
performed under a purge of dry nitrogen (50 ml/min). Aliquots 
of SIM or SDPs or physical mix (PM) of SIM and carrier, were 
accurately weighed (1-5 mg) and sealed in aluminum pans. 
Samples were heated by a ramp method to a temperature of 
200°C at a heating rate of 10°C/min. An empty aluminum pan 
was utilized as the reference. Calibration and validation of the 
instrument was performed with an indium reference standard 
prior to the start of the study.
Hot stage microscopy (HSM)
HSM was carried out using an Olympus BX51 (Olympus Optical 
Co. Ltd., Tokyo, Japan) polarizing optical microscope equipped 
with a Linkam LTS350 hot stage (Linkam Scientific Instruments 
Ltd., Surrey England) and Linkam TMS94 programmable 
temperature controller. SIM API or SDP were placed on a glass 
slide and gradually heated at 5°C/min until 200°C. Photographs 
were taken at RT and near the melting point of SIM, using 
Olympus C-7070 Digital Camera (7.1 megapixel, 4× optical 
zoom).
X-ray powder diffractometry (XRPD)
The XRPD patterns of SIM, SDPs and PM of SIM and carriers 
were obtained using a Bruker D8 Discover instrument. Each 
sample was placed and flattened with a glass slide to obtain a good 
surface texture and inserted in the cavity of an aluminum sample 
holder. The sample holder and detector were moved in a circular 
path during measurement of the powder pattern, to determine 
the angles of scattered radiation and to reduce preferred sample 
orientation. The samples were irradiated with monochromatized 
Ni filtered CuKa anode radiation (01542 nm). Samples were 
analyzed using a step width of 0.02° and 2q between 2° and 40° 
2q, at ambient temperature.
Fourier transform-infra red (FT-IR)
FT-IR spectra were obtained using a Bruker Tensor 27 FT-IR 
spectrometer (Bruker Optics, Ettlingen, Germany) equipped 
with deuterated triglycine sulfate detector. A background scan 
was performed prior to analysis. The spectra were an average 
of 16 scans at a resolution of 4/cm over the frequency range of 
4000-400/cm. KBr discs containing SIM, SDPs or PM of SIM 
and carrier were prepared using a manually operated hydraulic 
press (Specac, Kent, UK). Analysis of the spectra was performed 
using the OPUS Data Collection Program (V 1.1). The samples 
for infrared analysis and the KBr were dried for at least an hour 
prior to analysis in a drying oven (Specacabinet, Kent, UK) at 
32°C ± 0.5°C.
Formulation and characterization of ODTs
ODTs containing 20 mg SIM/tablet were formulated by weighing 
and blending the drug, SIM or SIM SDPs equivalent to a dose of 20 
mg/unit tablet of 300 mg with Mannitol 200, CP, Raspberry flavor 
and Mint flavor using a plastic resealable polythene bag [Table 1]. 
Magnesium stearate was then added and blended for a further 5 
min in a plastic resealable polythene bag. The blend was used to 
prepare ODTs weighing 300 mg by compression on an 8 station 
rotary tablet press fitted with 13 mm flat beveled edge toolings (Riva 
Piccola, Hampshire, UK). ODTs were characterized for uniformity 
of weight, hardness, tensile strength (TS), friability, porosity, DT 
using BP methods and as described by us previously.[15,23]
Analysis of SIM content
The SIM content of SDPs and tablets was determined using the 
high performance liquid chromatography (HPLC) analysis as 
described in the USP,[24] under the section, “USP monographs: 
SIM tablets.”
An appropriate quantity of the SIM SDP equivalent to 1-2 mg 
of SIM was accurately weighed or in case of ODT small volume 
of water was added and swirled to disintegrate and then suitably 
diluted using the HPLC sample diluting solution (1:4 of water 
pH 4.0 and acetonitrile) to obtain a concentration of about 
0.1-0.2 mg/ml of SIM. The solution was filtered and analyzed 
for drug content using HPLC analysis using a Perkin Elmer 
Series 200 Model S200 A/S and a 250 mm × 4.6 mm, Gemini 
5 μ C18 column, at 45°C. The mobile phase used consisted of 
acetonitrile and buffer pH 4.5 solution at 65:35 v/v. A flow rate of 
1.5 ml/min was used and analysis was carried out by ultraviolet 
(UV) spectrophotometer at 238 nm. A total volume of 20 μl of 
the extracted SIM sample was injected by autosampler and the 
assayed content of the drug was calculated using the calibration 
equation generated from the standards prepared within the 
concentration range of 0.0156-0.25 mg/ml.
Table 1: Formulation composition of ODTs
Formulation ODT001 (% w/w) ODT002 (% w/w)
Solid dispersion 
(SIM: Kollidon® CL-SF)
13.34 —
SIM — 6.67
Parteck® Mannitol 200 84.56 86.23
Kollidon® CL-SF — 5.00
Magnesium stearate 0.50 0.50
Raspberry 0.80 0.80
Mint 0.80 0.80
Total blend (% w/w) 100.00 100.00
ODTs: Orodispersible tablets, SIM: Simvastatin
Pabari, et al.: Orodispersible tablets of simvastatin spray dried solid dispersion
54 International Journal of Pharmaceutical Investigation | April 2014 | Vol 4 | Issue 2
Drug release from ODTs
SIM release from the ODTs was determined in the dissolution 
apparatus 2 and the procedure outlined in the BP 2008[22] under 
the monograph of SIM tablets was used. The dissolution medium 
used was 900 ml of 0.01 M sodium dihydrogen orthophosphate 
containing 0.5% w/v of sodium dodecyl sulfate and adjusted to pH 
7.0 with 1M sodium hydroxide. The paddle was set to rotate at 50 
rpm. Samples (20 ml) were withdrawn at various time points of 
5, 10, 20, 30 and 60 min, filtered using 0.45 um filter and 10 ml of 
the filtrate added to 0.1 g pre-washed manganese (IV) oxide and 
the absorbance was measured at 247 nm and 257 nm by UV visible 
(UV-vis) spectrophotometer (Libra S22 UV-vis Spectrophotometer, 
Biochrom, UK). The total content of SIM in the medium was 
calculated using the differences in absorbance at 247 nm and at 
257 nm and using the absorbance values from SIM standards. 
Withdrawn samples were replaced using fresh dissolution medium. 
Results are presented as the cumulative amount of drug release.
Statistical analysis
The results obtained are expressed as a mean ± standard 
deviation calculated using Microsoft excel (Redmond, WA, USA) 
software. Statistical analysis was performed using SPSS version 
15.0 for windows (SPSS, Inc., Chicago, IL, USA). Post hoc 
analysis was performed using Tukey. P < 0.05 was considered 
to be statistically significant.
RESULTS AND DISCUSSION
Characterization of SIM SDPs
The particle size of SIM API, carriers and corresponding aqueous 
dispersions is illustrated in Table 2. The median particle size 
(D50%) of SIM API was small at 7.39 μm and was similar to 
the D50% of CP and CS at 4.06 and 11.73 μm respectively. SSG 
showed a D50% of 42.66 μm. The size distribution across all 
samples was narrow as indicated by the span value of 1.20-2.32. 
When dispersed in water, SIM API showed about 2-fold increase 
in D50% to 16.08 μm [Table 2]. A similar, 2-3-fold increase in 
median particle size was observed when SIM was dispersed with 
the carriers, CP or SSG or CS, in an aqueous medium.
Aqueous dispersion of SIM API showed highest very high span 
value of 8.67, indicating aggregates/clumping of SIM crystals as 
expected from its hydrophobicity. The addition of any hydrophilic 
carriers to the aqueous dispersion of SIM resulted in lower span 
values probably related to the dispersing effect of hydrophilic 
carriers on SIM. In general, narrow size distribution of the API 
contributes to a homogenous drug distribution during formulation 
hence resulting in the formulation with uniform drug content.[25]
The D50% of SD SIM was found to be similar to SIM API at ~7 
μm. The D50% of SDPs was in the range 5.76-12.09 μm, similar 
to the D50% of SIM and/or the carriers [Table 3]. The D50% of 
SDP with SSG was found to be similar to SIM API or SD SIM 
despite the significant difference (P < 0.005) between the D50% 
of respective aqueous feed dispersions [Tables 2 and 3].
The SIM content of SDPs containing CP or CS was found to 
be 45.36% and 47.89%, respectively, i.e., close to the 1:1 starting 
ratio of the drug to carrier [Table 3]. For SDP formulated 
with SSG, the SIM content was higher at 71.59%, at nearly 
a 3:1 ratio of the drug to carrier, indicating loss of the carrier 
[Table 3]. The high SIM content in SDP containing SSG can 
also be related to the loss of the swelled SSG during spray 
drying, possibly through settling of the swelled SSG in the 
feed solution and resulting in a SIM rich feed suspension. 
A similar observation was reported by Gonnissen et al.,[16] 
when spray drying aqueous suspensions containing SSG. 
The authors reported that swelled SSG could have led to the 
formation of comparatively coarser gel-like droplets during 
spray drying, leading to its preferential deposition on the spray 
dryer chamber walls.
Product recovery of SD SIM was high at 60.40% [Table 3], while 
for SDPs was 3-fold lower at 21.07-27.73%, probably related to the 
higher viscosity of aqueous dispersions and hence larger residual 
feed dispersions from the aqueous dispersions.
Morphology of SIM SDPs
Scanning electron microscopy (SEM) showed SIM API to be 
elongated crystals [Figure 2a], which was in agreement with 
the observations of Jun et al.[26] SD SIM also showed similar 
crystals although these appear to be shorter as a result of 
fragmentation probably due to exposure to the shear forces 
encountered during spray drying [Figure 2b]. The morphology 
of the carriers ranged from irregular, crumpled to nearly smooth 
surface microparticulate morphology for the SSG as expected 
for starch granules [Figure 2c, e and g]. Corresponding SDPs 
of carriers and SIM showed morphology similar to the carrier 
and interestingly a carrier coated SIM crystals for SDPs with 
CP and CS was observed [Figure 2d and h]. For SSG, the 
Table 2: Particle size analysis of drug/carries 
only and corresponding aqueous dispersions of 
SIM only and in combination with carrier
API/
carrier
D50% 
(μm)
Span Aqueous 
dispersions
D50% 
(μm)
Span
SIM 7.39±0.03 1.71±0.01 SIM only 16.08±1.78 8.67±1.65
CP 11.73±0.03 2.32±0.04 SIM+CP 25.15±0.39 2.43±0.05
SSG 42.66±0.41 1.20±0.01 SIM+SSG 104.2±3.94 2.79±0.42
CS 4.06±0.16 1.89±0.04 SIM+CS 12.75±0.41 2.53±0.04
SIM: Simvastatin, CP: Crospovidone, SSG: Sodium starch glycollate, 
CS: Calcium silicate, API: Active pharmaceutical ingredient
Table 3: Characteristics of solid SD SIM and 
SIM SDPs
Drug/SDP D50% ( μm) Span Assayed SIM 
content (%)
SDP 
yield (%)
SIM (SD) 7.19±0.07 1.72±0.15 N/A 60.40
SDP CP 12.09±0.55 1.68±0.03 45.36±0.11 21.07
SDP SSG 7.45±0.19 1.89±0.10 71.59±4.79 21.87
SDP CS 5.76±0.42 2.09±0.08 47.89±3.11 27.73
SIM: Simvastatin, SD: Spray dried, SDP: Solid dispersion, CP: Crospovidone, SSG: 
Sodium starch glycollate, CS: Calcium silicate
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SDP showed the presence of unchanged SIM crystals and 
SSG granules [Figure 2f]. This morphology for SSG and SIM 
suggests a non-homogenous mixture which indicates that 
non-homogenous dispersions of SSG and SIM resulting in 
settling of the larger swollen SSG particles from the aqueous 
feed dispersions resulting in the higher SIM content observed 
for this SDP [Table 3].
Rheology of SIM SDPs
From the data in Table 4, SDP of SIM with CP or CS showed 
excellent rheological property, greatly improved compared to 
that of SIM API. This could be due to the coating of the API by 
CP and CS [Figure 2d and h]. A free-flowing rheology of the 
product is a critical parameter for formulation of uniform weight 
tablets particularly at high tableting speeds.[27] The Carr’s index 
and rheology of SDP containing SSG was similar to that of SIM 
API. This was related to the non-homogeneity and higher SIM 
content of this SDP [Tables 3, 4 and Figure 2f]. The lowest bulk 
density of the SDP containing CP suggests that particles could fit 
more compactly,[28] while the SDP consisting of CS were found 
to show highest density amongst all SDP and SIM API, probably 
related to its small D50% of 5.76 μm.
Solid state analysis of SDPs
DSC
DSC thermograms (Tg) of SIM API and SD SIM were found to 
be similar, a sharp endotherm at 140.01°C [Figure 3a (a and c)], 
close to the literature value of 139.5°C,[26] corresponding to the 
melting point of the crystalline SIM. On cooling and reheating, 
SIM API or SIM SD showed a glass transition at 34.70°C 
corresponding to the Tg of the drug and was similar to the 
literature value of 35°C [Figure 3A (b and d)].[9] Spray drying 
aqueous dispersions of SIM API therefore did not result in 
changes to its crystalline form.
DSC Tg of the single component of the superdisintegrant 
carrier CP or SSG exhibited a broad endotherm typical of 
amorphous substances [Figure 3b (a) and c (a)].[29] On the 
other hand, DSC Tg for CS, over the temperature range 
scanned, did not reveal any event [Figure 3d (a)] as was 
reported by Sharma et al.[30] This phenomenon was related to 
its relatively high melting point of 1700°C (Huber Engineered 
materials).
The DSC Tgs of the physical mixtures (PM) of SIM with CP or 
SSG showed two endothermic events attributed to each single 
component [Figure 3b (c) and c (c)]. For PM CS and SIM, 
one event corresponding to the melting point of SIM API was 
obtained as was expected since CS did not show any thermal event 
over the temperature range of the thermal analysis [Figure 3d (c)]. 
Therefore, it suggests that SIM and CP or SSG or CS when 
physically mixed forms a heterogeneous mix, with no interaction 
or changes in crystallinity of SIM.
Table 4: Density and rheological property of SIM and its SDP
Carrier/SDP Bulk density (g/cc) Tapped density (g/cc) Carr’s index (%) Flowabilitya
SIM 0.2169±0.02 0.2629±0.02 17.50 Fair
SDP CP 0.1172±0.00 0.1230±0.00 4.72 Excellent
SDP SSG 0.1598±0.01 0.1976±0.01 19.13 Fair
SDP CS 0.2500±0.00 0.2778±0.00 10.01 Excellent
aCarr’s index fl owability – ≤10%: Excellent, 11-15%: Good, 16-20%: Fair, 21-25%: Poor, fl uid, 26-31%: Poor, cohesive, 32-73%: Very poor, >38%: Extremely poor. 
SIM: Simvastatin, SDP: Solid dispersion, CP: Crospovidone, SSG: Sodium starch glycollate, CS: Calcium silicate
Figure 2: Scanning electron microscopy images of (a) simvastatin 
(SIM) active pharmaceutical ingredient, (b) spray dried SIM, (c) 
crospovidone (CP), (d) solid dispersion (SDP) of SIM with CP, (e) 
sodium starch glycollate (SSG), (f) SDP of SIM with SSG, (g) calcium 
silicate (CS), (h) SDP of SIM with CS
a
c
e
g
b
d
f
h Figure 3: Differential scanning calorimetry thermogram of simvastatin 
(SIM) (a): (a) active pharmaceutical ingredient (API) (b) API (rerun 
after cooling) (c) spray dried (SD) (d) SD (rerun after cooling), (b): (a) 
crospovidone (CP) (b) solid dispersion SIM:CP (c) physical mix (PM) 
SIM:CP, (c): (a) sodium starch glycollate (SSG), (b) SD SIM:SSG 
(c) PM SIM:SSG, (d): (a) calcium silicate (CS), (b) SD SIM:CS (c) 
PM SIM:CS
a
c
b
d
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Tgs of SD SDP of SIM with CP and CS [Figure 3b (b) and d (b)] 
were similar to the Tgs of their corresponding PM confirming 
crytallinity of SIM and no interaction with SIM and the carrier 
used. On the other hand, SD SDP of SIM with SSG [Figure 
3c (b)] showed one endothermic event corresponding to the 
crystalline SIM in its original polymorphic form. The absence 
of an endothermic peak corresponding to the SSG component 
was related to the loss of SSG during spray drying resulting in 
SIM rich SDP and the heterogenous SDP formed as shown in 
Figure 2f.
HSM
HSM was performed to visualize SDP morphology, morphological 
changes of the SDP on heating and to support the DSC analysis. 
HSM images for the SIM API in Figure 4a and SD SIM in 
Figure 4c showed SIM crystals at RT which are similar in 
morphology to that observed by SEM [Figure 2a]. At the higher 
temperature of 130-133°C, the crystals showed onset of melting 
[Figure 4b and d], which was consistent with that observed by 
DSC [Figure 3a (a and c)]. HSM images of the SDP of SIM 
in CP or CS [Figures 4e and i] demonstrated the presence of 
small sized crystals of SIM at RT as aggregates due to the carrier 
coating of SIM as was observed by SEM [Figure 2d and h]. As 
the temperature increased to 130-133°C, the crystals started to 
melt [Figure 4f and j] confirming the presence of crystalline 
SIM in the SDP. SDP with SSG [Figure 4g] showed crystalline 
SIM as smaller crystals, similar to SD SIM, as observed by SEM 
[Figure 2f], which melted at the higher temperature of 130-133°C 
[Figure 4h].
X-ray powder diffraction (XRPD)
XRPD of SIM API and its corresponding PM and SDP with each 
of the 3 carriers showed the presence of numerous distinct peaks at 
different diffraction angles of 2q, corresponding to those of crystalline 
SIM [Figure 5], similar to XRD diffraction pattern of SIM reported 
in the literature.[26,31] This confirms the presence of crystalline SIM 
in the SDP.
FT-IR
FT-IR spectrum of the SIM API and each of the 3 carriers, CP, 
CS and SSG showed characteristic peaks [Figure 6] as reported 
in the literature.[9,26,31-35] The spectrum of the PM and SDP of 
SIM in CP or SSG or CS was found to be a superimposition of 
the respective individual pure components and did not indicate 
any interactions occurring between the SIM and carriers. This 
therefore supports that SIM is present in its original stable 
crystalline form in these SDPs.[36]
Formulation and characterization of ODTs
Based on the SDP data observed, SDP with CP showed highest 
size of 12.09 μm contributing to the lowest Carr’s index and best 
rheological properties and hence SDP containing CP was used to 
formulate ODTs and was compared with ODTs prepared using 
Figure 5: X-ray powder diffraction patterns of (a) background 
measurement, (b) simvastatin (SIM), physical mix of SIM with (e) 
calcium silicate (CS), (f) crospovidone (CP), (h) sodium starch glycollate 
(SSG), solid dispersion of SIM in (c) CS, (d) CP, (g) SSG
Table 5: Characteristics of ODTs prepared using SDP containing CP and a blend of SIM with CP
SIM Turret speed (rpm) Weight (mg) Hardness (N) TS1 N/mm2 Friability 
(%)
Porosity 
(%)
DT (s) Drug content 
(%)
SDP SIM:CP 7 304.80±1.22 51.86±3.89 0.1014 0.16 20.88 19.17±6.08 92.91±2.13
49 296.23±8.46 35.48±9.83 0.0693 0.24 23.48 15.17±3.49 98.95±6.76
Blend SIM:CP 7 303.93±2.66 55.91±4.48 0.1092 0.19 21.85 13.33±3.67 95.55±3.41
49 283.47±15.6 32.03±9.05 0.0628 Failed 26.02 * *
*ODTs formed were soft and breaking as they were being compressed, therefore ODTs produced were not suﬃ  cient to perform all the characterization tests. SIM: 
Simvastatin, ODTs: Orodispersible tablets, SDP: Solid dispersion, CP: Crospovidone, DT: Disintegration time, TS: Tensile strength
Figure 4: Hot stage microscopy pictures at room temperature (a, c, e, 
g) and at 130-133°C (b, d, f, h) for simvastatin active pharmaceutical 
ingredient (a, b), spray dried simvastatin (c, d), solid dispersion of 
simvastatin in (e, f) crospovidone, (g, h) sodium starch glycollate and 
(i, j) calcium silicate
a
c
e
g
i
b
d
f
h
j
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a blend of SIM with CP. It can be observed from the Table 5 
that the characteristics of the ODT containing a blend of SIM 
with CP, such as weight variation, hardness, TS and friability 
were similar to that of ODTs containing SDP with CP at the 
lower turret speed of 7 rpm. No significant difference was found 
between the DT and assayed drug content of ODTs prepared 
using SDP containing CP and ODTs prepared using a blend 
of SIM with CP (P > 0.05). Compressibility of a material is 
measured by its ability to be reduced in volume as a result of an 
applied pressure. [37] Hence lower the porosity of the tablets higher 
is the compressibility of the material. The porosity of ODTs 
containing SIM SDPs was lower than the tablets containing 
SIM API indicating the higher compressibility of SIM SDPs 
compared to SIM API.
Interestingly, at the higher turret speed of 49 rpm, the blend 
containing SDP of SIM with CP resulted in ODTs with 
lower weight variation, probably related to a consistent flow 
properties and hence consistent die filling. In comparison, ODTs 
prepared from the blend of SIM with CP showed higher weight 
variation. SD materials are known to have improved flow and 
compressibility, hence such materials are easier to scale up and 
tablet at higher speeds. The ODTs containing SDP of SIM with 
CP also showed lower porosity, higher hardness and TS and were 
not friable [Table 5]. In contrast ODTs containing the blend 
of SIM with CP showed poor compressibility reflected by the 
higher porosity values of these ODTs as well as poor mechanical 
strengths as shown by their high friability and breaking. Sufficient 
ODTs could not be produced from this batch to allow all the 
characterization tests to be carried out.
ODTs containing the SDP of SIM with CP showed a higher 
dissolution compared to the ODTs containing a blend of SIM with 
CP and the commercial innovator product, Zocor® (ANOVA, P 
< 0.05) [Figure 7]. Both ODTs showed a much higher release 
of SIM of 102.04 ± 2.50 and 94.48 ± 1.63%, respectively at the 
earlier time point of 5 min compared to 19.27% ± 5.32% SIM 
released from the Zocor® tablets. The lower amount of SIM 
released from Zocor® can be attributed to its higher DT of 9.08 
min as it is a conventional oral tablet compared to the rapid DT 
of the ODTs at <20 s.
Higher SIM dissolution from ODTs containing ODTs prepared 
using SDP containing CP compared with ODTs prepared using a 
blend of SIM with CP (P < 0.05) could be related to the intimate 
mix of disintegrant carrier and SIM in the SDP that may facilitate 
disintegration to primary SIM particles.
CONCLUSIONS
SDPs of SIM with hydrophilic superdisintegrant carriers 
CP and CS showed narrow size distribution, excellent 
rheology and >90% SIM recovery. Moreover, SIM in the 
SDP was retained in its original stable crystalline form. No 
interaction, amorphous formation, polymorphic transition or 
degradation of SIM following formulation as SDPs in each 
of the disintegrant carrier used was observed. SDPs with CP 
showed high compactability and compressibility which are 
critical parameters for ease of tableting. Tablet blend consisting 
SDPs with CP showed ease of tableting which was maintained 
at high tablet turret speed of 49 rpm. In comparison, tablet 
blend consisting of SIM and CP could only be tableted at the 
lower speed of 7 rpm.
ODTs formulated using SIM SDP with CP showed a higher 
extent of dissolution compared to the ODTs containing SIM 
and CP or the commercially available SIM Zocor® tablets. 
This was related to the facilitated disintegration of SIM to 
primary drug particles as a result of the intimate mix of CP 
and SIM in the SDP. SDPs of hydrophobic crystalline drugs in 
a hydrophilic superdisintegrant carrier may provide a flowable, 
compressible, stable and easily scalable direct compression 
matrix, offering an alternative formulation approach for ODTs 
of poorly soluble drugs.
Figure 6: Fourier transform-infra red spectra of (a) simvastatin (SIM) 
active pharmaceutical ingredient, (b) (a) crospovidone (CP), (b) solid 
dispersion (SDP) of SIM: CP, (c) physical mix (PM) of SIM:CP, (c) 
(a) sodium starch glycollate (SSG), (b) SDP of SIM:SSG, (c) PM of 
SIM:SSG, (d) (a) calcium silicate (CS), (b) SDP of SIM: CS, (c) PM 
of SIM:CS
a
b
c
d
Figure 7: Drug release profi le from orodispersible tablets prepared 
using a blend of simvastatin and crospovidone, its corresponding solid 
dispersions and Zocor® tablets
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